P009 Inflammatory cytokines in relapsing-remitting multiple sclerosis (RRMS) patients

Conclusions Our findings revealed the increased IL-27 and IL-33 levels in patients' group. In conclusion, the inhibition of IL-27 and IL-33 might be a novel and promising therapeutic strategy, especially in the therapy of autoimmune inflammatory diseases. IL-27 and IL-33 play pivotal roles in development of MS and might be a specific marker and therapeutic target for MS inhibition. As important of cytokines in pathogenesis of neurodegenerative diseases, future therapeutic approach for molecular inhibitors should be designed for regulation of disorders progression.
Source: Multiple Sclerosis and Related Disorders - Category: Neurology Source Type: research